Back to search results

Psoriasis Treatment Outcomes with AI and Human Support

This study is looking at new ways to help people with psoriasis stick to their treatment plan. It's testing if artificial intelligence (AI) video calls or weekly video calls with study staff can help you use your betamethasone dipropionate cream (BD) more consistently, compared to standard care. Researchers want to see if these video interactions are practical and how patients feel about talking with AI in a healthcare setting. They'll also measure how well people use their medication over four weeks. You might be able to join if you are at least 18 years old, have psoriasis that can be treated with BD, live in the US, speak English, and have a mobile device that can handle video calls.

Study design
This interventional study plans to enroll up to 15 participants with psoriasis. Participants will be randomly assigned to one of three groups: AI video visits, human video calls, or standard care.
What's involved
You would receive betamethasone dipropionate cream (BD) and either have weekly virtual visits with an AI program, weekly video calls from study staff, or a single follow-up visit in 4 weeks.
Compensation
Not stated in the trial record.
Follow-up
Your attitudes, trust, and comfort with AI interactions will be assessed at Week 4, and medication adherence will be evaluated over a 4-week period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07391423

Assessing Psoriasis Treatment Outcomes

Not Yet Recruiting
NAAges 18+InterventionalHealth services
Wake Forest University Health Sciences
~15 participants
Updated 2026-08-04 on ClinicalTrials.gov
What's tested:Artificial intelligenceHumanStandard of Care

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Ability to implement AIGPP system and Rate of dropout in AIGPP trial arm
Measured over Week 4
+1 more outcome measured

Conditions

Psoriasis

Explore related trials

Psoriasis

Where it's being run

1 sites across 1 states
North Carolina1

Study leadership

  • Steven R Feldman, M.D., Ph.D. · PRINCIPAL_INVESTIGATOR · Wake Forest University Health Sciences

Who to contact

Irma M Richardson, MHA
[email protected]
336-716-2903
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patients ≥18 years of age
Patients with a current diagnosis of psoriasis suitable for treatment with topical Betamethasone (BD)
Patients who live in the United States
Patients with a sufficient command of the English language
Patients with a mobile device able to at least operate at 25 frames per second (FPS).

Exclusion

Patients less than the age of 18
Patients with severe or unstable comorbid conditions
Patient who are pregnant or breastfeeding
Patients with any other skin conditions that prohibit or confound the ability of the investigator to interpret skin findings
Patients that are taking concomitant topical or systemic therapy for the treatment of psoriasis and/or phototherapy
Patients without mobile devices able to at least operate at 25 frames per second (FPS).
Patients without a current diagnosis of psoriasis suitable for treatment with topical BD

What this trial measures

  • Ability to implement AIGPP system and Rate of dropout in AIGPP trial armWeek 4

    One primary outcome of the study is the feasibility of AIGPP interactions with psoriasis patients, which will be measured as whether we can create \& implement the AIGPP system and the dropout rate in the AIGPP arm

  • Thematic analysis of qualitative interviews regarding psoriasis patients' attitudes, trust, and comfort levels with AIGPP interactions in a healthcare settingWeek 4

    Another primary outcome will be psoriasis patients' attitudes, trust, and comfort levels with AIGPP interactions in a healthcare setting, which will be measured by semi-structured qualitative interviews analyzed via a thematic analysis.